North American Bioproducts Corporation – Trademark Portfolio
Entity Type: 03
North American Bioproducts Corporation holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ACETOBAN, BACTENIX, and BIO-FERM. The owner is based in Duluth, GA.
Corporate Support Center, Building 200
1815 Satellite Boulevard
Duluth, GA 30097
Showing of trademarks Trademarks
Trademark Classifications
North American Bioproducts Corporation's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does North American Bioproducts Corporation have?
North American Bioproducts Corporation has 9 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned, 5 cancelled.
What trademark classes does North American Bioproducts Corporation file in?
North American Bioproducts Corporation files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are North American Bioproducts Corporation's most well-known trademarks?
North American Bioproducts Corporation's registered trademark portfolio includes well-known marks such as ACETOBAN, BACTENIX, and BIO-FERM. These are among 3 currently registered trademarks in the portfolio.
What is North American Bioproducts Corporation's trademark registration success rate?
North American Bioproducts Corporation has a 33% trademark registration rate, with 3 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.